BMY
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical company with a dominant political signal being $30.5M in 2024 doctor payments via E.R. Squibb & Sons, L.L.C. and executive branch holdings by Donald J. Trump valued up to $100,000.
Govt Dependence
35/100
Regulatory Density
85/100
Lobbying Intensity
0/100
Political Signal
NEUTRAL
BusinessWhat BMY does
Bristol-Myers Squibb Company discovers, develops, and commercializes pharmaceuticals for oncology, immunology, cardiovascular, and neuroscience diseases. Revenue is generated through global sales of prescription drugs, with significant income from key products like Opdivo and Eliquis. The company also engages in partnerships and acquisitions to expand its pipeline.
6 months past · 3 months futureBMY activity timeline
Congress
buy
sell
Insider · Form 4
open-market buy
Hedge fund · 13F
opened
+ added
− trimmed
closed
holds
Bills
past action (this ticker)
upcoming markup (sector)
★ carveout (this ticker)
109 trading days ·
6 congressional trades shown
·
0 insider buys
·
4 13F filings
·
0 past bill actions
·
3 upcoming markups
Executive Branch ConflictsBMY held by Trump-administration officials
2 cabinet/senior officials reported BMY positions in OGE Form 278 disclosures across 3 filings.
Lifetime Government AwardsBMY federal contracts by year
$18M
total awarded · 2022–2026
80
contracts on file
2025
peak year ($8M)
Top contracts by award amount
$911K
Department of Veterans Affairs
2026-01-13
REVLIMID, POMALYST, CAMZYOS SPECIALTY PHARMACEUTICALS
$848K
Department of Veterans Affairs
2025-12-31
REVLIMID, POMALYST, CAMZYOS SPECIALTY PHARMACEUTICALS
$670K
Department of Veterans Affairs
2025-05-15
EMERGENCY BREYANZI INFUSION
$379K
Department of Veterans Affairs
2026-03-13
ABECMA FOR CAR-T
$364K
Department of Veterans Affairs
2026-05-29
BREYANZI CAR T-TRANSPLANT
5 years · 80 contracts
Smart Money · 13F HoldingsHedge funds holding BMY
$6.00B
Total BMY held by tracked 13F funds
40
Funds with BMY positions
+40
Funds opened this quarter
Millennium Management
$480M
opened
2024-12-31
Citadel Advisors
$357M
opened
2024-06-30
Citadel Advisors
$352M
opened
2024-09-30
Millennium Management
$268M
opened
2024-09-30
Citadel Advisors
$268M
opened
2024-03-31
Two Sigma Investments
$256M
opened
2024-06-30
Two Sigma Investments
$251M
opened
9 overlap
2025-12-31
Two Sigma Investments
$249M
opened
2024-03-31
32 more 13F positions tracked · quarterly delta charts available in member dashboard
Politicians Trading BMYMembers of Congress with recent BMY positions
9 politicians traded BMY across 49 disclosed transactions totaling $564K (last 730 days).
Greed score = composite of trade frequency, volume & recency across the politician's entire history (not just BMY). 0-30 LOW · 30-60 MID · 60+ HIGH.
Ro Khanna
12 buys
11 sells
$307K
2026-01-29
LOW · 0
Jefferson Shreve
2 sells
$65K
2025-05-12
LOW · 0
Julie Johnson
2 buys
6 sells
$64K
2025-12-18
LOW · 15
Gilbert Ray Cisneros
2 buys
2 sells
$32K
2025-12-19
HIGH · 61
Virginia Foxx
2 buys
2 sells
$32K
2025-06-24
LOW · 1
Julia Letlow
1 buy
1 sell
$16K
2025-04-28
LOW · 1
Greg Landsman
2 sells
$16K
2025-03-27
LOW · 0
Val T. Hoyle
2 buys
$16K
2024-10-29
LOW · 0
Tommy Tuberville
2 sells
$16K
2025-04-15
LOW · 8
Congressional TradesWho in Congress is trading BMY
2026-01-23
Ro Khanna
Purchase
$1,001 - $15,000
2026-01-29
Ro Khanna
Sale
$15,001 - $50,000
2025-12-18
Julie Johnson
Sale
$1,001 - $15,000
2024-10-23
Julia Letlow
Purchase
$1,001 - $15,000
447d late
2025-04-28
Julia Letlow
Sale
$1,001 - $15,000
260d late
2025-12-19
Gilbert Ray Cisneros
Purchase
$1,001 - $15,000
2025-11-12
Gilbert Ray Cisneros
Purchase
$1,001 - $15,000
2025-11-13
Julie Johnson
Sale
$1,001 - $15,000
2025-11-03
Ro Khanna
Purchase
$1,001 - $15,000
2025-10-09
Gilbert Ray Cisneros
Sale
$1,001 - $15,000
2025-10-09
Gilbert Ray Cisneros
sale
$1,001 - $15,000
2025-09-05
Ro Khanna
purchase
$1,001 - $15,000
30+ trades on file · most recent 2026-02-06
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills Affecting BMYLive legislation impacting this stock
S.164 · 117th
Advancing Education on Biosimilars Act of 2021
HR.1843 · 119th
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
HR.1288 · 118th
Holding Countries Accountable for Negligent Chemical and Biological Programs Act
HR.1352 · 118th
Increasing Access to Biosimilars Act of 2023
S.775 · 118th
Increasing Transparency in Generic Drug Applications Act
S.935 · 118th
Fair Accountability and Innovative Research Drug Pricing Act of 2023
HR.1790 · 118th
Biologics Competition Act of 2023
HR.6897 · 118th
Synthetic Biology and Active Pharmaceutical Ingredients Act
HR.6903 · 118th
Stockpiling Active Pharmaceutical Ingredients Act
HR.6895 · 118th
Defense Production and Active Pharmaceutical Ingredients Act
Political ProfileWhere BMY sits in Washington
[object Object]
STRUCTURAL: Executive branch holdings by Trump ($50,001-$100,000) and Democrat donation alignment ($5,000 to Joyce Beatty). EVIDENTIARY: No recent corporate insider buys in 180-day window (get_corporate_insider_signal.score 0, tier F), but three Form 4 buys in 2025 totaling ~$412K. Net: Mixed signals with high regulatory density but low trading activity.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
Pharmaceutical pricing legislationCongress"Recent bill_impacts array shows 8 bills with impact_ratios 0.0001-0.0002, each estimated to impact revenue by $15M-$22.5M."
-
Increased transparency in doctor paymentsCMS"get_political_influence.doctor_payments shows $30.5M in 2024 payments via E.R. Squibb & Sons, L.L.C., potentially subject to disclosure regulations."
Regulatory opportunities
-
Federal contracts for pharmaceuticalsDepartment of Veterans Affairs"get_government_precedent.federal_contracts_summary[0] shows $17.5M total obligation across 80 contracts, including with VA."
-
Executive branch stock holdings may indicate favorable policy viewsWhite House"get_executive_branch_exposure.by_ticker[0].holdings shows Donald J. Trump holds BMY stock valued $50,001-$100,000."
Capitol Hill AlliesChampions & critics
Congressional champions
Congressional critics
- No specific congressional critics identified.
Member intelligence layer
Live signals + predictions for BMY — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades BMY
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord
Frequently AskedAbout BMY & political exposure
Does Bristol-Myers Squibb Company (BMY) hold federal contracts?
Yes. Bristol-Myers Squibb Company has 80 federal contract awards totaling $17,509,624, primarily from agencies including Department of Justice, Department of Veterans Affairs. See full contract list and amounts on this page.
Which Trump cabinet officials own BMY stock?
2 Trump cabinet members or senior White House staff have disclosed holdings in BMY on their OGE 278 financial disclosures, including Donald J. Trump, Lori Chavez-DeRemer. See the Cabinet Conflicts panel for details.
Has Congress traded BMY stock?
412 congressional trades by 45 unique members of Congress, most recently on 2026-01-29. See the Congressional Trading panel for politician-by-politician breakdown.
What is BMY political risk profile?
Government dependence: 35/100. Lobbying intensity: 0/100. Political signal: neutral. Donor party split: R 0% / D 100%.
How does GovGreed track BMY political activity?
GovGreed integrates STOCK Act congressional trade disclosures, FEC contributions, OGE executive-branch disclosures, USASpending federal contracts, Senate LDA lobbying filings, and SEC Form 4 corporate insider trades into a single queryable graph. BMY data is updated daily from these official federal sources.